Cargando…

Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study

BACKGROUND: Darunavir has been proven efficacious for antiretroviral-experienced HIV-1-infected patients in randomized trials. However, effectiveness of darunavir-based salvage therapy is understudied in routine care in Brazil. METHODS: Retrospective cohort study of HIV-1-infected patients from thre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribeiro, Karina Mota, Biscione, Fernando Martin, Westin, Mateus Rodrigues, Machado, Danielle Pessoa, Greco, Dirceu Bartolomeu, Tupinambás, Unaí
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425192/ https://www.ncbi.nlm.nih.gov/pubmed/23916454 http://dx.doi.org/10.1016/j.bjid.2013.04.001

Ejemplares similares

Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte, Brazil - 1996-2012
por: Tupinambás, Unaí, et al.
Publicado: (2013)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy
por: Deshwal, Rajesh, et al.
Publicado: (2019)

Profile of drug–drug interactions and impact on the effectiveness of antiretroviral therapy among patients living with HIV followed at an Infectious Diseases Referral Center in Belo Horizonte, Brazil
por: Pontelo, Betânia Maira, et al.
Publicado: (2020)

Social and immunological differences among uninfected Brazilians exposed or unexposed to human immunodeficiency virus-infected partners
por: Silva, Maria Luiza, et al.
Publicado: (2014)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

Low eligibility for hepatitis B treatment in the Brazilian public health system
por: Scarponi, Cristiane Faria Oliveira, et al.
Publicado: (2022)

Virology and Immunology of Bats
por: Schountz, Tony
Publicado: (2013)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort
por: Chaussade, Hélène, et al.
Publicado: (2020)

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
por: Spinner, Christoph D, et al.
Publicado: (2020)

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2020)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

31st Brazilian Online Society for Virology (SBV) 2020 Annual Meeting
por: de Arruda, Luciana Barros, et al.
Publicado: (2021)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Long-term virologic and immunologic responses on darunavir/ritonavir – containing regimens among highly antiretroviral therapy-experienced patients: 7-year follow-up of a prospective cohort study in São Paulo, Brazil
por: Vidal, José E., et al.
Publicado: (2017)

The 32nd Brazilian Society of Virology (SBV) 2021 Annual Meeting
por: Vaslin, Maite Freitas Silva, et al.
Publicado: (2022)

33rd Brazilian Society for Virology (SBV) 2022 Annual Meeting
por: Vaslin, Maite Freitas Silva, et al.
Publicado: (2023)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics
por: Joshi, Shivali S., et al.
Publicado: (2020)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

Trends and predictors of HIV-1 acquired drug resistance in Minas Gerais, Brazil: 2002–2012
por: Duani, Helena, et al.
Publicado: (2016)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study
por: Huhn, Gregory D., et al.
Publicado: (2019)

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Combating HIV resistance – focus on darunavir
por: Tremblay, Cécile L
Publicado: (2008)

Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009)

Darunavir pharmacokinetics throughout pregnancy and postpartum
por: Lambert, John, et al.
Publicado: (2014)

The prognosis of patients with dissociated virological and immunological responses to HAART
por: Jevtovic, DJ, et al.
Publicado: (2010)

Immunological and virological aspects of HIV cell-to-cell transfer
por: Schwartz, Olivier
Publicado: (2009)

Virology and Immunology Researchers Evolve with the Viruses We Study
por: Russell, Rodney S.
Publicado: (2020)

Insights into the virologic and immunologic features of SARS-COV-2
por: Polat, Ceylan, et al.
Publicado: (2021)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ap86drrvrqnvajg73knskq0m0l